Leslie Orne

What an interesting read on the shift from traditional patient recruitment methods in rare disease! Learn more about how to optimize patient-driven site engagement in my team member’s blog: https://bit.ly/4eHoBn4

3

In #NeurodegenerativeDisease news, specifically on an experimental treatment for #ALS, with this new #strategic partnership is penned between Dewpoint Therapeutics and Mitsubishi Tanabe Pharma America. ⚛️ The asset is the former's drug, designed "to address the accumulation of a protein into toxic structures that lead to neuronal dysfunction in people with ALS." 🤝 The alliance would grant MTP exclusive rights to license, upon achieving certain developmental milestones. ⚕️ This would add to MTP's existing US-marketed ALS treatment, #Radicava https://lnkd.in/evayrVv4' #Dewpoint #Mitsubishi #Pharma #Biopharma #Healthcare

6

In a recent CRA webinar on evolving business models for DTx (Digital Therapeutics) Rhett Johnson and Andy Parece discussed with a panel of industry leaders, Richard DeNunzio, Omar Manejwala, M.D., and Brion Raymond, how events in the past year, from introduction of new HSPCS billing codes to Pear Therapeutics’ bankruptcy and the transition of some DTx manufacturers to alternative business models, impact their companies. Each panelist discussed business models their company is employing, including prescription digital therapeutics, collaboration with employers to fund solutions and with pharma companies to collaborate partner in research and commercialization. The discussion covered the drivers behind the choice of each business model as well as their advantages, and showed how they are related to the specific product, indication and available clinical evidence base. To learn more and watch the webinar recording, click here: https://lnkd.in/gjdbCBTd #DigitalTherapeutics

14

When a crisis hits, swift and effective communication is key. Boston Biopharma is here to guide you through high-stakes situations with our expert crisis communication strategies. We ensure that your messaging is clear, consistent, and impactful, helping you navigate challenges with confidence. Stay prepared and resilient with our support. #BiotechPharma #Biotech #pharmaceutical #pharma #healthcare #medicine #BostonBioPharmaConsultants #marketing

1

We started out Q1 with cautious optimism and the numbers continue to show the confidence was warranted. Biopharma M&A activity more than doubled nationally during the year’s first three months, coinciding with a rebound in venture capital deals as well as a flurry of IPOs. These are all good signs that the drug development cycle is normalizing and should translate into additional funding being available at the seed and Series A stages. Certain to be on the minds of funders and startups attending #AlignSummit24 on Thursday! https://lnkd.in/erEiJm6S  

112

5 Comments

📨 Potential implications exist in regard to #LCM and #strategies regarding market exclusivity, see below, the latest from the FTC, sending warning letters to ten major pharma companies in an attempt to continue challenging and cracking down on #JunkPatents. 📂 The claims are around 'inaccurate or improper' patents in place which essentially block competition and keep drug prices high. Many big-name prescription brands are included in this round of probes. 2️⃣ 0️⃣ : "The FTC is challenging the patents of 20 different brand name products, claiming that their listings in the FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations—more commonly known as the Orange Book—are improper or inaccurate." 🤔 Are your brands affected? ❓ How might actions against you or your competitors affect your LCM strategy? https://lnkd.in/eVuapvWJ #LifeCycleManagement #RegulatoryAffairs #Policy #FTC #FederalTradeCommission #OrangeBook #PharmaPatents #AntiTrust #Pharma

1

Our Senior Director of Program and Alliance Management, Sarah Hudson, PhD, PMP®, will speak at the Portfolio Strategy & Decision Making for Biopharma Summit on building effective cross-functional teams in #pharma. She will be sharing how strong cross-functional collaboration powers our work in revolutionizing a new class of targeted RNA therapeutics through our Antibody-Oligonucleotide Conjugate (AOC) platform. Our success in developing innovative therapies for rare muscle diseases depends on strong collaboration and clear communication throughout every level of our organization. Learn more about our AOC platform: https://lnkd.in/dH-56XKM

103

1 Comment

How has Parkinson’s disease (PD) evolved over the years? Ryan Case, PhD, Senior Medical Director, recently shared his insights on the shifting landscape with pharmaphorum. The discussion explored his perspective on the latest advancements and exciting areas of innovation that are driving progress, as well as how MTPA’s guiding philosophy – the KAITEKI principle – shapes our work and commitment to people living with Parkinson’s disease. We applaud Ryan’s dedication to the PD community and are proud to have him on our team. Read the full article here: https://bit.ly/4fA9hZU

42

Check out Outcome Capital's Q1 #Biopharma market segment report, including the Outcome index tracker, #transaction highlights, and strategic analysis from Outcome Capital's #lifesciences deal team. - With record amounts of dry powder, a noticeable uptick in "mega" Series A rounds seen as firms look for proven management in high-growth segments - Increase in #Biotech / #Pharma M&A as strategics deploy cash to refresh pipelines and pivot to new areas of growth - Next Generation of safer, easier and effective #radiopharmaceuticals spur renewal of licensing, M&A and VC activity

22

1 Comment

Facing bandwidth constraints and digital overload in reaching healthcare decision-makers? You're not alone. Our latest case study examines how two biopharma companies leveraged FormularyDecisions® to revolutionize their HCDM engagement strategy, improving information exchange and stakeholder connections while optimizing resources. Discover their practical approach to maximizing HCDM outreach in today's complex landscape: https://ow.ly/eEzv50Uw3Kq

13

In an article on AstraZeneca’s Farxiga blockbuster drug, PharmaVoice quotes Daniel Chancellor, Director of Thought Leadership at Norstella, Citeline's parent company: https://ow.ly/sCkr50TMSAl. The article also references Citeline’s “Billion Dollar Blueprint: The Journey to Blockbuster Status” report: https://ow.ly/RvuY50TMSAm. #BlockBusterDrugs #PharmaTrends #DrugDevelopment

18

In the new year, connected commercial teams will be best positioned to help HCPs navigate increasing therapeutic complexity. Matt Farrell, Dan Rizzo, and Brian Mahoney highlight commercial #lifesciences trends to look for this year. ⬇️ Check out all of the trends here: https://lnkd.in/gWxTmHi9 #biopharma #biotechnology 

64

Breaking ground in new modalities requires new, creative approaches to partnership. Tomoko Hanadate, Head of R&D Alliances, and Barbara Leyman, Chief Business Development Officer, Sutro Biopharma, share insights on how dynamic deal structures are critical to navigating complex challenges associated with advancing the next generation of #ImmunoOncology therapies.  If you’re an ambitious organization that shares our vision of turning innovative science into VALUE for patients, get in touch: https://lnkd.in/gyp4qwMS #ChangingTomorrow 

388

6 Comments

Great insights from Tomoko Hanadate, Head of R&D Alliances, Astellas Pharma and Barbara Leyman, Chief Business Development Officer, Sutro Biopharma on the importance of dynamic deal structures in advancing next-gen #ImmunoOncology therapies. The complexity of modern R&D requires not just innovation in science, but in how we partner to bring these breakthroughs to patients. Excited to see how new, creative collaborations will continue to drive progress in this transformative space. #ChangingTomorrow #Collaboration #Innovation #CancerResearch #CancerTherapeutics #SutroBio $STRO

16

1 Comment

In an article on AstraZeneca’s Farxiga blockbuster drug, PharmaVoice quotes Daniel Chancellor, Director of Thought Leadership at Norstella, Citeline's parent company: https://ow.ly/qmv650TMSa6. The article also references Citeline’s “Billion Dollar Blueprint: The Journey to Blockbuster Status” report: https://ow.ly/hJPB50TMSa5. #BlockBusterDrugs #PharmaTrends #DrugDevelopment

23

As part of AstraZeneca’s focus on sustainable science, we have set ourselves the ambitious goal to introduce electronic product information (ePI) across all medicines, while ensuring flexibility for patients to access product information through alternative ways if needed. The introduction of ePI brings with it a host of benefits for the planet, patients, and healthcare systems, including: 🌍 Improved accessibility to the most up-to-date information on medicines, available in multiple different languages. 💊 More efficient and wider availability of medicines through digitalisation of labels and quick implementation of label changes. 🍃 Lower environmental impact. If ePI was introduced across all AstraZeneca products, it could potentially save an average of 500,000 trees and 1.6bn litres of water each year. Learn more: https://lnkd.in/gJC-fwtd #WhatScienceCanDo

8

Three of my fav people on stage at #VeevaSummit next week! Looking forward to learning about the power of connected data and software and why it's essential to power key customer engagement!

14

Unlocking the potential of oncology assets isn't just about groundbreaking science – it's about asking the right questions from day one. 💡 In this International Pharmaceutical Industry Journal article, Jason Gilbody, Principal, Strategic Consulting at Envision Pharma Group and co-lead of Envision Oncology Solutions, explores how strategic insights can help shape successful commercialization. From informed decision-making to effective product launches, discover why the questions you ask at the outset are crucial for your asset's journey to market. Read the full article to learn how smart questioning can revolutionize your oncology asset's path from development to success. 👇 https://lnkd.in/eSh_7Ag8 #Oncology #LifeSciences #HealthcareInnovation

35